The problem with clinical trials
Clinical trials are an important step in developing and testing new treatments.
How well medicines work and how safe they are can change depending on a person’s age, gender, ethnicity and more, so it is vital that clinical trials include a diverse range of participants. Black men are twice as likely to be diagnosed with prostate cancer compared to White men, and 2.5 times more likely to die from the disease. However, despite Black men being more likely to get it, they are under-represented in prostate cancer trials.
As a result, clinical trials do not account for the differences in benefits and/or side effects of treatments in Black men. This means that we don’t know whether treatments will work as well or if they could cause worse side effects in Black men compared to White men. There is also concern that Black men are more likely to decline or not complete their prostate cancer treatment.
1 in 4 Black men will be diagnosed with